Levosimendan Reduces Lung Injury in a Canine Model of Cardiopulmonary Bypass

Background and Objectives To explore the lung-protective effect of levosimendan (LS) during cardiopulmonary bypass in a canine model by determining the wet/dry weight (W/D) ratio of lung tissue, malonaldehyde (MDA) and superoxide dismutase (SOD) concentrations, and performing a histological evaluation.